Latest urinary retention Stories

People using intermittent catheters no longer need to re-use their catheters due to a new Medicare policy effective April 1, 2008. The change affects nearly 1 million individuals living with spinal cord injury, multiple sclerosis and spina bifida, as well as those who have other permanent conditions requiring bladder management or experience urinary incontinence or retention. Backed by Coloplast Corp., members of Congress and the incontinence care community, the new policy eliminates...

By Annie Freeda Cruez MOST irritating. Annoying, to say the least, for it comes in dribs and drabs. This is the lot of men suffering from enlarged prostate, writes ANNIE FREEDA CRUEZ. It is called the "old man's disease" for it's rare in men below the age of 40. Generally, about half the men in their 60s have the symptoms, which worsen with age. The incidence of enlarged prostate or benign prostatic hyperplasia (BPH) in Malaysia is of concern, says Dr Rohan Malek, head of the Urology...

Nymox Pharmaceutical Corporation (NASDAQ:NYMX) has developed an innovative new treatment for BPH, NX-1207, which has now entered Phase 3, the final stage of drug testing before applying for FDA approval. Every day across the U.S., millions of men cope with the symptoms of an enlarged prostate (BPH or benign prostatic hyperplasia). The symptoms include problems with urination such as having to urinate more frequently and having to get up repeatedly during the night. The long-term...

Nymox Pharmaceutical Corporation (NASDAQ: NYMX) is pleased to announce that detailed new peer-reviewed data from the most recently completed clinical studies of NX-1207, the Company's drug in development for benign prostatic hyperplasia (BPH) will be presented at several upcoming meetings of the American Urological Association to be held in Chicago, San Diego and Santa Ana Pueblo. The Nymox investigational drug has entered Phase 3 development. NX-1207 is a novel drug developed by Nymox...

GlaxoSmithKline has announced that the FDA has approved Avodart in combination with tamsulosin for the treatment of symptomatic enlarged prostate, a disease that is said to affect half of all men over 50 years old. The FDA approval was based on two-year results of the CombAT study, one of the largest clinical trials to date of men with enlarged prostate. The CombAT study is the first long-term assessment of the combination of Avodart and an alpha-blocker, the company said. The CombAT study...

PHILADELPHIA, June 19 /PRNewswire-FirstCall/ -- GlaxoSmithKline today announced that the U.S. Food and Drug Administration (FDA) has approved AVODART (dutasteride) in combination with tamsulosin for the treatment of symptomatic enlarged prostate, a disease that affects half of all men over 50 years old. The new indication reflects emerging research showing the combination of the two medicines treats the symptoms of enlarged prostate more effectively than either medicine alone. "The...

By Spatafora, Sebastiano Conti, Giario; Perachino, Massimo; Casarico, Antonio; Et al Key words: Diagnosis - Drug therapy - Lower urinary tract symptoms - Practice guidelines - Prostatic diseases - Prostatic hyperplasia - Surgery ABSTRACT Background and scope: Despite the high prevalence and huge socio- economic impact of benign prostatic hyperplasia (BPH) in Italy, no national guidelines have been produced so far. This is a summary of the first Italian guidelines on the diagnosis and...

NEW YORK (Reuters Health) - Tolterodine treatment, sold in the US under the name of Detro, is part of a class of medications called antimuscarinics, which prevent bladder contractions, according to researchers who also found that tolterodine is a well-tolerated treatment for overactive bladder in men with bladder outlet obstruction and the drug does not seem to cause urinary retention, Antimuscarinic agents are typically not given to elderly men with bladder outlet obstruction,...

NEW YORK -- Pot smokers could be putting themselves at risk for developing bladder cancer, according to the results of a study of middle-aged men who were seen at two Veterans Administration facilities.Marijuana smoking "might be an even more potent stimulant" of malignancy than cigarette smoking, Dr. Martha K. Terris of the Medical College of Georgia in Augusta and her colleagues write in the medical journal Urology.Terris and her team point out that head and neck and lung cancers...

ROCHESTER, Minn.  --  Men who experience signs and symptoms of a prostate obstruction resulting from benign prostatic hyperplasia (BPH) are three times more likely than other men to develop chronic kidney disease, according to findings of a Mayo Clinic study published in this month's edition of Kidney International. "This is the first study on the topic to sample the general community," says Andrew Rule, M.D., the Mayo Clinic kidney specialist who conducted the study with...